These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 25593115)

  • 1. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
    Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
    Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [
    Warfvinge CF; Gustafsson J; Roth D; Tennvall J; Svensson J; Bernhardt P; Åkesson A; Wieslander E; Sundlöv A; Sjögreen Gleisner K
    J Nucl Med; 2024 Jul; 65(7):1070-1075. PubMed ID: 38724277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [
    Hebert K; Santoro L; Monnier M; Castan F; Berkane I; Assénat E; Fersing C; Gélibert P; Pouget JP; Bardiès M; Kotzki PO; Deshayes E
    J Nucl Med; 2024 Jun; 65(6):923-930. PubMed ID: 38637144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
    Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of
    Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
    J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
    Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
    Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.
    Ezziddin S; Reichmann K; Yong-Hing C; Damm M; Risse J; Ahmadzadehfar H; Logvinski T; Guhlke S; Biersack HJ; Sabet A
    Nuklearmedizin; 2013; 52(5):170-7. PubMed ID: 23963021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized
    Del Prete M; Buteau FA; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
    Alsadik S; Yusuf S; Al-Nahhas A
    Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During
    Hagmarker L; Svensson J; Rydén T; van Essen M; Sundlöv A; Gleisner KS; Gjertsson P; Bernhardt P
    J Nucl Med; 2019 Oct; 60(10):1406-1413. PubMed ID: 30902877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
    Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
    J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
    Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
    J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.